| | 73573-87-2 Basic information More.. |
| Product Name: | Formoterol | | Synonyms: | n-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide;FORMOTEROL TARTARATE;FormoterolBase;Formoterol Fumarate 43229-80-7 / Base;Eformoterol;Formamide, N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, rel-;Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (R*,R*)-;Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (R*,R*)-(+-)- | | CAS: | 73573-87-2 | | MF: | C19H24N2O4 | | MW: | 344.4 | | EINECS: | | | Mol File: | 73573-87-2.mol |  |
Use
Formoterol (Foradil) isalso a lipophilic (log P= 1.6) and long-acting β2-agonist. Ithas 3'-formylamino ( β-directing) and 4 OH groups on onephenyl ring and a lipophilic -directing N-isopropyl-pmethoxyphenylgroup on the nitrogen atom. Its long DOA(12 hours), which is comparable to that of salmeterol, hasbeen suggested to result from its association with the membranelipid bilayer, from which it gradually diffuses to provideprolonged stimulation of β2 receptors and its resistanceto MAO and COMT. Formoterol has a much faster onset ofaction than does salmeterol as result of its lower lipophilicity.Both of these long-acting drugs are used by inhalationand are recommended for maintenance treatment of asthma,usually in conjunction with an inhaled corticosteroid.
|
|
73573-87-2
Recommend Suppliers |
|